Summary
Bristol-Myers Squibb Company (BMY) filed an 8-K report on January 22, 2008, to announce a significant change in its Board of Directors. The company elected Togo D. West, Jr. as a new director, effective immediately. This appointment increases the size of the Board to eleven members. Mr. West's addition is intended to strengthen the board's expertise, as he brings experience from his roles as chairman of TLI Leadership Group and Noblis, Inc. His independence has been confirmed according to NYSE and company standards, and he will serve on key committees, including Compensation and Management Development, and Directors and Corporate Governance. Investors should note that Mr. West's appointment is part of the company's ongoing governance efforts. He will be compensated according to the standard non-employee director pay structure, which includes an annual retainer, per-meeting fees, and deferred share units. The company also attached the press release announcing this appointment as an exhibit to the filing, providing further details for interested parties. This move signals a focus on experienced leadership and independent oversight within the company's governance framework.
Key Highlights
- 1Togo D. West, Jr. has been elected to the Bristol-Myers Squibb Board of Directors, effective January 22, 2008.
- 2The size of the Board of Directors has been increased to eleven members.
- 3Mr. West is considered independent under New York Stock Exchange and company standards.
- 4Mr. West will serve on the Compensation and Management Development Committee and the Committee on Directors and Corporate Governance.
- 5Mr. West's compensation as a director includes an annual retainer of $60,000, a $2,000 per-meeting fee, and an annual award of $110,000 in deferred share units.
- 6The election was made upon the recommendation of the Committee on Directors and Corporate Governance.
- 7A press release detailing the appointment is attached as Exhibit 99.1 to the filing.